DSIP (delta sleep-inducing peptide): what it is, how people use it, and what the evidence shows

DSIP is one of the oldest names in the sleep-peptide world, and one where the honest story sits unusually far from the marketing. It circulates in biohacking forums, sleep-optimization podcasts, and wellness-clinic menus as a peptide that switches on deep, restorative sleep and dials down stress, usually with the age and thinness of the evidence quietly trimmed away. This page puts them back. It explains what DSIP actually is, what researchers have and have not shown, what is known and unknown about its safety, and what users report, with a primary source for every claim. It is educational only, and nothing here is medical advice. For the wider context of how peptides fit together, start with our cross-therapy explainer on what peptides are, and for the most-searched recovery peptide see the companion BPC-157 overview.

What is DSIP?

DSIP is a naturally occurring nonapeptide, a chain of nine amino acids, and unlike most research peptides on the market it was found in the body rather than designed for one. It was isolated from the cerebral venous blood of rabbits during sleep experiments by the Schoenenberger-Monnier group in Basel in 1977 (Kovalzon & Strekalova, 2006), and its structure was worked out and confirmed by synthesis the following year: amino-acid analysis and sequencing showed it to be Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, and it was named the “Delta Sleep-Inducing Peptide”. A foundational review describes it as a nonapeptide of molecular weight 849, which makes it a small molecule by peptide standards.

The name is a promise the science never fully kept. DSIP was christened for the deep, slow-wave (delta) sleep it appeared to promote when infused into animals, and the same review reports that it seemed to induce mainly delta-sleep in rabbits, rats, mice, and humans, while in cats the effect on REM sleep was more pronounced, an early hint that its effects are not even consistent across species. Two facts are worth carrying forward. First, nearly half a century after its discovery, researchers still have not isolated a DSIP gene, a precursor protein, or a receptor, so how (or whether) the body itself uses this sequence remains undefined (Kovalzon & Strekalova, 2006). Second, none of this, by itself, says whether injecting synthetic DSIP is safe or useful in a person. Those are separate questions, and the rest of this page takes them one at a time.

How is DSIP thought to work?

The honest answer is that nobody really knows, and that uncertainty is the single most important thing to understand about DSIP. Unlike peptides with a well-mapped target, it has no confirmed receptor and no agreed mechanism of action. The broad early literature described a molecule that seemed to touch many systems at once: a 1984 review catalogs reported effects on electrophysiological activity, neurotransmitter levels in the brain, circadian and locomotor patterns, hormonal levels, psychological performance, and the activity of neuropharmacological drugs including their withdrawal. A profile that wide and that non-specific is usually a sign that the underlying mechanism has not been pinned down, not evidence that the molecule does everything at once.

The most candid assessment comes from a 2006 review in the Journal of Neurochemistry whose title says the quiet part out loud: DSIP is “a still unresolved riddle.” Its authors conclude that the link between DSIP and sleep has never been further characterized, in part because of the lack of isolation of the DSIP gene, protein and possible related receptor. They go further, judging that the hypothesis regarding DSIP as a sleep factor is extremely poorly documented and still weak, and that despite decades of interest its natural occurrence and biological activity still remains obscure. When marketing describes a mechanism, “it supports your sleep architecture” or “it regulates your stress hormones,” what actually sits underneath is a decades-old, unresolved question about what this peptide does at all. That is not a reason to assume it does nothing. It is a reason to distrust any confident mechanistic story told about it.

What is DSIP studied and marketed for?

DSIP is marketed and studied mainly for two goals: deeper sleep and lower stress. It is important to read those as areas of old, unsettled investigation rather than proven uses, because the wording of an advertisement (“restores your deep sleep”) and the wording of the science (“produced a small, non-significant change in a sleep laboratory”) are not the same claim. On the sleep side, the pitch follows directly from the name: a peptide that induces delta sleep should, the story goes, deepen your slow-wave sleep and leave you more rested. On the stress side, the marketing leans on scattered early reports that DSIP influenced hormonal levels and even drug-withdrawal responses, which vendors stretch into general “anti-stress,” calm, and recovery claims that the original observations never established.

Because this overview is the definitional entry point, the network’s deeper, evidence-first page examines the central claim in detail rather than asserting it here: our nootropic publication breaks down what the research on DSIP for sleep actually shows, including the small human trials and why the strongest recent signal comes from mice. For the pineal, sleep-and-circadian peptide that sits on the very same 2026 advisory-committee agenda, see our epitalon overview.

Treat both areas as “being investigated,” not “established.” The marketing describes the outcome people hope for; the evidence section below describes what has actually been demonstrated, which is a much thinner thing. The gap between the two is the entire reason this page exists.

What does the evidence actually show?

Almost all of the human evidence for DSIP is thin, decades old, and mixed, and the most encouraging recent findings are in mice rather than people. The most rigorous human tests are small double-blind studies from the 1980s and early 1990s. In one double-blind, matched-pairs study, 16 chronic insomniac patients received DSIP intravenously, and although the researchers measured modest objective gains such as higher sleep efficiency and shorter sleep latency, they judged those effects weak and possibly incidental and concluded that short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit. An earlier polysomnographic trial in chronic insomniacs saw only small changes in sleep architecture, most of them not statistically significant, and its authors concluded that sleep improvement under DSIP treatment is of little clinical significance. Sustained scientific interest largely faded after that era, which is itself a quiet data point: a compound that had genuinely delivered in people would not usually be abandoned.

The more eye-catching recent work is preclinical, and, importantly, it does not test the plain peptide that vendors sell. A 2024 study in Frontiers in Pharmacology engineered a DSIP fusion peptide designed to cross the blood-brain barrier and tested it in a chemically induced (PCPA) model of insomnia in mice, reporting reduced wakefulness and shifts in serotonin, melatonin, and dopamine (Mu et al., 2024). That is a genuine result, but it is a mouse study, and the fusion construct it tested is a different molecule from the DSIP in a research vial. Put the record together and the honest reading is not that DSIP was proven useless. It is that the human trials that could show whether it helps people are sparse, old, and largely negative-to-neutral, while the newer and more promising work has not been reproduced in humans and used a re-engineered version of the peptide. Preclinical promise and human proof are different things, and DSIP sits almost entirely on the promise side of that line. Anyone presenting the mouse fusion-peptide data as if it were evidence for the vial is skipping the step that actually matters.

What are the reported side effects and safety unknowns?

DSIP’s human safety profile is largely unknown, because it has barely been studied in people and never in the long-term, repeated-injection way it is actually used. The small mid-century trials that exist did not report dramatic harms, but “no obvious problems in a handful of short, small studies” is not a safety record, and it says nothing about self-injecting an unregulated compound over months or years. Because there is no modern pharmacovigilance, no established human dose, and no characterized profile of drug interactions or long-term effects, the accurate statement is that the risks are largely uncharacterized rather than known to be low. “We have not looked carefully” and “it is safe” are very different sentences, and marketing routinely swaps the first for the second.

Layered on top of those biological unknowns is a product-quality problem specific to how DSIP is actually sold. Because it is not a regulated medicine, the “research use only” vials shipped by online vendors carry none of the guarantees a pharmacy product does, and that label by its own wording means the contents are not intended for human use. A peer-reviewed forensic analysis of falsified peptide products, most often obtained from illegal internet pharmacies, found low purity ranging between 5% and 75% for cysteine-containing peptides, high variation in the amount of drug per unit, and toxic elemental impurities including arsenic and lead at concentrations up to ten times the ICH toxicity limit for parenteral drugs. So the safety picture carries two layers of uncertainty at once: what an unstudied peptide does inside a human body over time, and whether the vial even contains what the label claims, at the purity and sterility an injection would require. Our hub explainer on what the evidence shows about peptide side effects walks through both layers in more detail.

Is DSIP banned in sport?

Yes, in practice. DSIP is not individually named on the World Anti-Doping Agency’s Prohibited List, but the US Anti-Doping Agency explains that experimental compounds not approved for human clinical use by any global regulatory authority fall under the list’s S0 category for non-approved substances and are prohibited in sport at all times. Because DSIP has no such approval anywhere, an athlete in a tested sport should treat it as banned.

What are people saying about DSIP?

The DSIP conversation is split almost down the middle. In 9 posts on X that our community tracker collected on July 18 and 19, 2026, users described three kinds of experience:

• Deeper sleep. Some users take it before bed for deep sleep and say they feel more rested, and one said it helps them function on fewer hours.
• Fading or no effect. One user said it worked for about a week for getting back to sleep and then left them unrested. Another listed DSIP among peptides that worked for them while noting that most people say they get nothing from it.
• Stacks. Users describe pairing DSIP with Selank and other peptides in routines aimed at sleep, stress and recovery, and keep experimenting with timing.

That spread, a few enthusiasts, a few people who felt it fade, and many who noticed nothing, looks a lot like the clinical record described above, where small controlled studies found little consistent benefit. It is still a small, two-day snapshot from one platform, not evidence either way. For the sleep question in more depth, our sister site covers what DSIP for sleep has actually been studied for.

How to think about DSIP

If you are weighing DSIP, the most useful move is to separate the chemistry from the claims. The chemistry is real and genuinely interesting, a small, naturally occurring nonapeptide discovered in sleep research half a century ago. The claims are mostly hope resting on a thin, dated, and largely negative-to-neutral human record, because the trials that would confirm a real sleep or stress benefit were small, old, and unconvincing, and the promising recent work is in mice using a re-engineered molecule.

If your actual goal is deeper, more consistent sleep or a calmer response to stress, start with that goal, ideally with a licensed clinician, who can look at what is genuinely disrupting your sleep, screen for conditions like sleep apnea or an anxiety or mood disorder, and weigh options such as cognitive behavioral therapy for insomnia, an approved medication where appropriate, or a change in routine.

Status: Not FDA-approved. What this status means.

Educational information only, not medical advice. Every scientific statement on this page is sourced to the primary references linked above. Updated October 12, 2026.